Key result
An amlodipine/olmesartan medoxomil-based regimen achieved systolic blood pressure targets at 12 weeks in 71.6% of black patients and 77.2% of non-black patients uncontrolled on prior monotherapy.
Why the study?
Does a fixed-dose amlodipine/olmesartan medoxomil-based regimen improve blood pressure control in black and non-black patients with hypertension uncontrolled on prior monotherapy?
Observational (n=999)
Does a fixed-dose amlodipine/olmesartan medoxomil-based regimen improve blood pressure control in black and non-black patients with hypertension uncontrolled on prior monotherapy?
Amlodipine/olmesartan medoxomil-based dose-titration effectively lowers blood pressure in both black and non-black patients with hypertension uncontrolled on prior monotherapy.
May support similar BP control rates with this regimen across races; leaves open need for randomized confirmation.
In this secondary analysis of a dose-titration study of patients with hypertension uncontrolled on prior monotherapy, blacks (n=234) and non-blacks (n=765) were switched to amlodipine (AML)/olmesartan medoxomil (OM) 5/20 mg, with uptitration every 4 weeks to AML/OM 5/40 mg and then AML/OM 10/40 mg to achieve a seated cuff blood pressure (SeBP) of <120/70 mm Hg. Hydrochlorothiazide 12.5 and 25 mg could be added if SeBP was ≥125/75 mm Hg. The cumulative proportions of patients achieving systolic SeBP <140 mm Hg (<130 mm Hg if diabetic) at 12 weeks were 71.6% for blacks and 77.2% for non-blacks. Mean SeBP change from baseline in blacks (mean baseline BP: 153.0/93.7 mm Hg) ranged from -11.7/-6.1 mm Hg for AML/OM 5/20 mg to -23.6/-12.9 mm Hg for AML/OM 10/40 mg +hydrochlorothiazide 25 mg (all P<.0001). Antihypertensive efficacy was maintained throughout the 24-hour dosing interval. An AML/OM-based regimen was effective in blacks with hypertension uncontrolled on prior monotherapy.
No takes yet. Share an insight, caveat, or question.
Nesbitt et al. (2013) conducted an observational in Hypertension uncontrolled on prior monotherapy (n=999). Amlodipine/olmesartan medoxomil vs. Non-blacks was evaluated on Cumulative proportion of patients achieving systolic SeBP <140 mm Hg (<130 mm Hg if diabetic) at 12 weeks. An amlodipine/olmesartan medoxomil-based regimen achieved systolic blood pressure targets at 12 weeks in 71.6% of black patients and 77.2% of non-black patients uncontrolled on prior monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: